Evidence map›Paper›PMID 27586381›Full record

ReviewNature reviews. Rheumatology2016

What rheumatologists need to know about innate lymphocytes.

Mark A Exley, George C Tsokos, Kingston H G Mills, Dirk Elewaut, Ben Mulhearn

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. The Herbal Combination ofFrontiers in pharmacology · 2022
    Article
  2. Article
  3. Review
  4. Review
  5. Eosinophils in Autoimmune Diseases.Frontiers in immunology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Mark A ExleyManchester Collaborative Centre for Inflammation Research (MCCIR), The University of Manchester, Grafton Street, Manchester M13 9NT, UK.
George C TsokosRheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, Massachusetts 02215, USA.
Kingston H G MillsSchool of Biochemistry and Immunology, Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse Street, Dublin 2, Ireland.
Dirk ElewautLaboratory for Molecular Immunology and Inflammation, Department of Rheumatology, University Hospital Ghent, De Pintelaan 185, 0K12B, B-9000 Ghent, Belgium.
Ben MulhearnManchester Collaborative Centre for Inflammation Research (MCCIR), The University of Manchester, Grafton Street, Manchester M13 9NT, UK.
Beth Israel Deaconess Medical Center · USCentre for Inflammation Research · GBGhent University Hospital · BETrinity College Dublin · IEUniversity of Manchester · GB

Funding

LYMPHOCYTE SIGNALING DEFECTS IN PATIENTS WITH LUPUSR01AI042269 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI TSOKOS, GEORGE C · 1998 to 2017
$6.8M
Obesity increased cancer risk by NKT cell depletion (PQ1)R21CA170194 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI EXLEY, MARK A · 2012 to 2013
$400k
NCI NIH HHS R21 CA170194NIAID NIH HHS R01 AI042269
6 · The paper itself

Abstract

Many rheumatic diseases are characterized by having an autoimmune background. Determining the mechanisms underlying autoimmunity is, therefore, important to further understand these diseases and to inform future lines of research aimed at developing new treatments and cures. As fast responders, innate lymphocytes have protective or pathogenic roles in the initiation as well as the maintenance of immune responses in general, and they contribute to tissue homeostasis, among other functions. Innate lymphocytes also seem to be involved in autoimmunity in particular. Since 2010, accumulating evidence clearly shows that different populations of innate lymphocytes have roles in responding to antigen-specific autoantibody and autoreactive T cells, thereby amplifying or attenuating disease processes. Cytotoxicity is a cardinal feature of many innate lymphocytes and can contribute to inflammatory tissue damage. Finally, innate lymphocytes can respond to biologic therapies for autoimmune diseases. Consequently, like TNF and other effector molecules, certain innate lymphocyte subsets might be appropriate therapeutic targets to ameliorate various autoimmune diseases. In this Review, we summarize the main characteristics and functions of innate lymphocyte subsets, and describe their roles in autoimmune disease. We also discuss how biologic therapies influence innate lymphocyte function and consider the potential for these cell subsets to act as future therapeutic targets.

Indexed as

Immunity, InnateAntirheumatic AgentsAutoantibodiesB-LymphocytesHumansImmunosuppressive AgentsMucosal-Associated Invariant T CellsNatural Killer T-CellsRheumatic DiseasesT-Lymphocyte SubsetsTumor Necrosis Factor-alphaAntirheumatic AgentsAutoantibodiesImmunosuppressive AgentsTumor Necrosis Factor-alpha

Identifiers

PMID27586381
OpenAlexW2507558572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.